Randy Schatzman, the former chief executive of Alder BioPharmaceuticals (NASDAQ: [[ticker:ALDR]]), has been appointed CEO of Bolt Biotherapeutics. He is also joining the Redwood City, CA, company’s board of directors. Schatzman was CEO of Alder from its founding in 2004 until last year, when he left the company. Bolt Bio raised $54 million in February … Continue reading “Bolt Biotherapeutics Taps Ex-Alder Executive Randy Schatzman as CEO”
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
Former Nightstar Exec Gregory Robinson Joins Akouos as Chief Scientific Officer
Gregory Robinson has joined Akouos as chief scientific officer, the same position he held at gene therapy developer Nightstar Therapeutics. Nightstar was acquired by Biogen (NASDAQ: [[ticker:BIIB]]) earlier this year. Robinson’s experience also includes positions at Agilis Biotherapeutics, Shire, and Eyetech Pharmaceuticals. In other moves, Akouos co-founder Michael McKenna expanded his role to full-time chief … Continue reading “Former Nightstar Exec Gregory Robinson Joins Akouos as Chief Scientific Officer”
Vir Bio Plans IPO to Fund Clinical Trials of Infectious Disease Drugs
Vir Biotechnology assembled its pipeline of infectious disease compounds through deal-making with other drug developers, along with financial support from blue-chip venture capital firms and the non-profit Bill & Melinda Gates Foundation. Now the biotech is turning to the public markets for the cash to continue clinical tests of its most advanced drug candidates. San … Continue reading “Vir Bio Plans IPO to Fund Clinical Trials of Infectious Disease Drugs”
Accent Therapeutics Taps Tango’s Shakti Narayan for CEO
Shakti Narayan has joined Accent Therapeutics as CEO and member of the company’s board of directors. Narayan comes to Lexington, MA-based Accent from Tango Therapeutics, where he was chief business officer for the past two years. His experience also includes positions at Johnson & Johnson Innovation and Nodality. Accent raised $40 million in Series A … Continue reading “Accent Therapeutics Taps Tango’s Shakti Narayan for CEO”
Former Alnylam Executive Soni Joins Reata Pharmaceuticals as CFO
Reata Pharmaceuticals (NASDAQ: [[ticker:RETA]]) has appointed Manmeet Soni to serve as chief financial officer and executive vice president. With Soni’s hire, James Wilson, CFO and executive vice president of strategy, will shift to a new role as Reata’s executive vice president of operations. Soni stepped down as CFO of Alnylam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]) last month. … Continue reading “Former Alnylam Executive Soni Joins Reata Pharmaceuticals as CFO”
Vertex Bets $950M on Semma and a Stem Cell Therapy for Diabetes
Vertex Pharmaceuticals is paying $950 million to acquire Semma Therapeutics, a biotech startup developing a stem cell therapy for type 1 diabetes. The deal announced Tuesday is Vertex’s first step into the diabetes field and is the latest in a string of moves the Boston company has made to diversify beyond its core franchise of … Continue reading “Vertex Bets $950M on Semma and a Stem Cell Therapy for Diabetes”
Patent Challenge to Alexion Proceeds, But No Amgen Biosimilar Yet
Three patents that extend the exclusivity of Alexion Pharmaceuticals’ franchise rare disease drug will now face a patent challenge from Amgen. On Friday, a court within the US Patent and Trademark Office agreed to a review of Amgen’s claims that three Alexion (NASDAQ: [[ticker:ALXN]]) patents covering its drug, eculizumab (Soliris), were anticipated or obvious, and … Continue reading “Patent Challenge to Alexion Proceeds, But No Amgen Biosimilar Yet”
Scholar Rock CFO Rhonda Chicko to Leave in September
Scholar Rock (NASDAQ: [[ticker:SRRK]]) announced that Rhonda Chicko, the company’s chief financial officer, is leaving to “pursue other opportunities.” The Cambridge, MA-based drug developer gave no other details about Chicko’s plans other than to say that she will stay on the job through Sept. 30 to help with the transition of her responsibilities. A search … Continue reading “Scholar Rock CFO Rhonda Chicko to Leave in September”
Azitra Appoints Mark Sampson Chief Scientific Officer
Mark Sampson has joined Azitra as chief scientific officer. Travis Whitfill, co-founder and chief science officer of the Farmington, CT-based company, will take on new roles as executive director of advanced technology and chair of the scientific advisory board. Sampson’s experience includes positions at Realm Therapeutics, Sterilox Technologies, and Warwick International. Atriza is developing microbiome-based … Continue reading “Azitra Appoints Mark Sampson Chief Scientific Officer”
Ex-Nektar Exec Maninder Hora Joins Amunix Pharmaceuticals C-Suite
Amunix Pharmaceuticals has appointed Maninder Hora to serve as chief technical operations officer, the same position he held at Nektar Therapeutics (NASDAQ: [[ticker:NKTR]]). Mountain View, CA-based Amunix is developing a type of cancer drug called a T cell engager using technology that the company says overcomes the limitations of these immunotherapies.
Sesen Bio’s Richard Fitzgerald to Depart, Monica Forbes Is Named CFO
Richard Fitzgerald, chief financial officer of Sesen Bio (NASDAQ: [[ticker:SESN]]) for the past 19 months, will leave the company on Aug. 30, the company announced Monday. Cambridge, MA-based Sesen gave no reason for Fitzgerald’s departure. Monica Forbes, the company’s vice president of finance, was promoted to CFO effective immediately. Sesen, formerly known as Eleven Biotherapeutics, … Continue reading “Sesen Bio’s Richard Fitzgerald to Depart, Monica Forbes Is Named CFO”
Space Venture’s Tom Neary Lands at SEngine as Chief Financial Officer
Tom Neary has been appointed chief financial officer of SEngine Precision Medicine. Neary most recently worked as CFO at Space Venture Partners, and prior to that as the top financial executive for Spaceflight Industries. His experience also includes positions at Microsoft (NASDAQ: [[ticker:MSFT]]). Seattle-based SEngine has commercialized a diagnostic test used to match a patient … Continue reading “Space Venture’s Tom Neary Lands at SEngine as Chief Financial Officer”
FibroGen Founder and CEO Thomas Neff Passes Away Unexpectedly
Thomas Neff, the founder, CEO, and chairman of FibroGen (NASDAQ: [[ticker:FGEN]]), has passed away. The San Francisco-based biotech did not disclose any details other than to say Neff’s death over the weekend was unexpected. Board member James Schoeneck has been named interim CEO while the company searches for Neff’s permanent successor. Neff founded FibroGen in … Continue reading “FibroGen Founder and CEO Thomas Neff Passes Away Unexpectedly”
Celgene to Sell Blockbuster Drug to Amgen for $13B to Close BMS Deal
Celgene is selling a blockbuster anti-inflammatory drug to Amgen for $13.4 billion cash, a deal needed to close the company’s pending $74 billion acquisition by Bristol-Myers Squibb. Bristol-Myers (NYSE: [[ticker:BMY]]) is still working to complete the proposed acquisition of Celgene (NASDAQ: [[ticker:CELG]]) that was announced in January. In June, Bristol-Myers said that Celgene drug apremilast … Continue reading “Celgene to Sell Blockbuster Drug to Amgen for $13B to Close BMS Deal”
GSK’s Cancer Comeback Continues With Data for Multiple Myeloma Drug
An experimental GlaxoSmithKline treatment for multiple myeloma has achieved the main goal of a key study, and the drug maker plans to file for regulatory approval by the end of this year. GlaxoSmithKline (NYSE: [[ticker:GSK]]) said Friday that treatment with its drug, belantamab mafodotin, showed a “clinically meaningful overall response rate” in the study. The … Continue reading “GSK’s Cancer Comeback Continues With Data for Multiple Myeloma Drug”
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
Biotech news tends to slow down in August but the past seven days have been busy for regulatory decisions. Three drugs and two devices won FDA nods. Not all companies were as fortunate. Several biotechs reported failed clinical trials or unfavorable FDA decisions. The most notable one might be the rejection of a Sarepta Therapeutics … Continue reading “Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More”
Frequency Therapeutics Names Dana Hilt Chief Medical Officer
Frequency Therapeutics has appointed Dana Hilt to serve as its chief medical officer, the same position he held at Lysosomal Therapeutics. His experience also includes positions at FORUM Pharmaceuticals, Guilford Pharmaceuticals, Ascend Pharmaceuticals, Critical Therapeutics, and Amgen (NASDAQ: [[ticker:AMGN]]). William Chin, Frequency’s interim CMO, will shift to a new role at the company as executive … Continue reading “Frequency Therapeutics Names Dana Hilt Chief Medical Officer”
Cadent Therapeutics Appoints John McBride CFO
John McBride has been appointed chief financial officer of Cadent Therapeutics. He was most recently the CFO of Syntimmune, which was acquired by Alexion Pharmaceuticals (NASDAQ: [[ticker:ALXN]]) last year. Cambridge, MA-based Cadent raised $40 million in financing last November to advance its lead drug into Phase 2 testing for two movement disorders.
UniQure Eliminates Chief Operating Officer Role, McMillan to Retire
UniQure (NASDAQ: [[ticker:QURE]]) is eliminating the chief operating officer position, which has been filled for the past two years by Scott McMillan. The gene therapy developer, which is based in the Netherlands and has US operations in Lexington, MA, said that McMillan will retire and two other executives are moving into different positions. Sander van … Continue reading “UniQure Eliminates Chief Operating Officer Role, McMillan to Retire”
Amgen Neuro Exec Marek Joins Axsome as Chief Commercial Officer
Axsome Therapeutics (NASDAQ: [[ticker:AXSM]]) has appointed David Marek to serve as chief commercial officer. Marek joins the New York biotech from Amgen (NASDAQ: [[ticker:AMGN]]), where he was vice president and general manager of the company’s neuroscience business unit. His experience also includes executive roles at WebMD and Saatchi & Saatchi Healthcare Advertising. Axsome is developing … Continue reading “Amgen Neuro Exec Marek Joins Axsome as Chief Commercial Officer”
Oncorus Adds $79.5M to Steer Cancer-Fighting Virus to Human Testing
Nearly four years ago, the FDA approved a therapy that uses a virus to infect tumor cells and break them down—the first such viral therapy for treating cancer. Oncorus CEO Ted Ashburn says there’s room to improve on these oncolytic viruses and their role in immunotherapy, and his biotech startup is getting ready to show … Continue reading “Oncorus Adds $79.5M to Steer Cancer-Fighting Virus to Human Testing”
Elanco’s $7.6B Deal With Bayer Bolsters Pets, Farm Animals Footprint
Elanco Animal Health, the veterinary sector’s fourth-largest company measured by revenue, is poised to leap to number two through a $7.6 billion cash and stock deal for Bayer’s animal health unit. The acquisition will help Elanco boost its business selling products for farm animals. But Elanco (NYSE: [[ticker:ELAN]]) notes that Bayer, which sells the popular … Continue reading “Elanco’s $7.6B Deal With Bayer Bolsters Pets, Farm Animals Footprint”
Genentech’s Sandra Horning to Retire, Levi Garraway Named Successor
Roche subsidiary Genentech announced Monday that Sandra Horning, chief medical officer and head of global product development since 2014, will retire at the end of the year. Horning joined Genentech in 2009 as a senior vice president. Levi Garraway has been appointed Horning’s successor. Garraway recently resigned from Eli Lilly (NYSE: [[ticker:LLY]]), where he was … Continue reading “Genentech’s Sandra Horning to Retire, Levi Garraway Named Successor”
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
The dog days of summer are here and IPO activity has slowed, but that hasn’t stopped some biotech companies from securing a place in the line leading to Wall Street. Late Friday, SpringWorks Therapeutics and Satsuma Pharmaceuticals filed paperwork to go public. SpringWorks spun out of Pfizer (NYSE: [[ticker:PFE]]) nearly two years ago, aiming to … Continue reading “Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs”
SpringWorks Therapeutics Appoints Francis Perier CFO
Francis Perier has been appointed chief financial officer of SpringWorks Therapeutics. Perier’s experience includes financial roles at Forest Laboratories, Bristol-Myers Squibb (NYSE: [[ticker:BMY]]), and Deloitte. Stamford, CT-based SpringWorks was spun out of Pfizer (NYSE: [[ticker:PFE]]) in 2017 with rights to four of the pharmaceutical giant’s drugs. In April, SpringWorks raised $125 million in Series B … Continue reading “SpringWorks Therapeutics Appoints Francis Perier CFO”
Motif Unveils New Name and $27.5M to Build Food Ingredients Pipeline
Plant-based meats and milks still use proteins, just not proteins that come from animals. Motif Ingredients has raised $27.5 million to build a pipeline of these animal-free protein ingredients. In addition to the new cash, Motif on Thursday also unveiled a new name: Motif FoodWorks. The Boston company says the name better connects its business … Continue reading “Motif Unveils New Name and $27.5M to Build Food Ingredients Pipeline”
Ex-Acceleron Exec Zeldin Named Immunovant Chief Medical Officer
Four months after stepping down from Acceleron Pharma (NASDAQ: [[ticker:XLRN]]) as chief medical officer, Robert Zeldin has been appointed to the chief medical position at Immunovant. Zeldin’s experience also includes roles at Ablynx, Merck (NYSE: [[ticker:MRK]]), and Novartis (NYSE: [[ticker:NVS]]). Immunovant, which splits its operations between New York and Basel, Switzerland, is developing treatments for … Continue reading “Ex-Acceleron Exec Zeldin Named Immunovant Chief Medical Officer”
GSK’s US President Bailey to Depart, EMD Serono Exec Named Successor
Jack Bailey, president of US pharmaceuticals for GlaxoSmithKline (NYSE: [[ticker:GSK]]), will step down from the role at the end of the year. The British pharmaceutical giant said Monday that Bailey will be succeeded by Maya Martinez-Davis, regional president of Latin America for EMD Serono, the biopharma business of Germany-based Merck KGaA. Martinez-Davis’s experience also includes … Continue reading “GSK’s US President Bailey to Depart, EMD Serono Exec Named Successor”
On Target Laboratories Taps Philips Healthcare’s Barys for CEO
Christopher Barys has been appointed CEO of On Target Laboratories. Barys is also joining the West Lafayette, IN-based company’s board of directors. He succeeds former CEO Martin Low. Barys comes to On Target from Philips Healthcare, where he led the company’s image guided therapy group. Barys’s experience also includes positions at Medtronic (NYSE: [[ticker:MDT]]) and … Continue reading “On Target Laboratories Taps Philips Healthcare’s Barys for CEO”
Orthofix Medical CEO Mason to Retire, Serbousek Appointed Successor
Brad Mason, president and CEO of Orthofix Medical (NASDAQ: [[ticker:OFIX]]) since 2013, will retire on Oct. 31. The Lewisville, TX-based company has named Jon Serbousek his successor. Orthofix said Serbousek will serve as president of the company’s global spine business until Mason’s retirement. Serbousek comes to Orthofix from Pinnacle Advisory Partners, where he was managing general partner. … Continue reading “Orthofix Medical CEO Mason to Retire, Serbousek Appointed Successor”
Vor Biopharma Appoints Neon’s Robert Ang President & CEO
Vor Biopharma has appointed Robert Ang to serve as president and CEO. Ang joins Cambridge, MA-based Vor from Neon Therapeutics, where he was chief business officer. His experience also includes positions at Bavarian Nordic, Cadence Pharmaceuticals, and Frazier Healthcare Ventures. In February, Vor raised $42 million in Series A financing to support development of a … Continue reading “Vor Biopharma Appoints Neon’s Robert Ang President & CEO”
Melinta Therapeutics CEO Johnson Resigns, Successor Search Underway
After less than one year on the job, Melinta Therapeutics (NASDAQ: [[ticker:MLNT]]) CEO John Johnson has resigned “due to changes in the company’s circumstances and in order to pursue other opportunities,” the antibiotics developer announced Friday. He also stepped down from the Morristown, NJ-based company’s board of directors. Melinta said Johnson will serve as acting … Continue reading “Melinta Therapeutics CEO Johnson Resigns, Successor Search Underway”
Cleave Therapeutics Appoints Amy Burroughs CEO, Scott Harris COO
Cleave Therapeutics appointed Amy Burroughs to serve as its CEO. The San Francisco drug developer also announced $12 million in financing to advance cancer drug candidate CB-5339 through Phase 1 testing in acute myeloid leukemia. The financing was led by 5AM Ventures, Celgene (NASDAQ: [[ticker:CELG]]), Orbimed, U.S. Venture Partners, Arcus Ventures, Astellas Venture Management, and … Continue reading “Cleave Therapeutics Appoints Amy Burroughs CEO, Scott Harris COO”
Assembly Bio Taps Former Gilead Sciences Exec McHutchison for CEO
Days after stepping down as chief scientific officer of Gilead Sciences (NASDAQ: [[ticker:GILD]]), John McHutchison has surfaced as the new president and CEO of South San Francisco-based Assembly Biosciences (NASDAQ: [[ticker:ASMB]]). Assembly said Wednesday that McHutchison will also join the company’s board of directors. Last month, Gilead announced that McHutchison would leave after nearly a … Continue reading “Assembly Bio Taps Former Gilead Sciences Exec McHutchison for CEO”
Ribon Therapeutics Taps Sudha Parasuraman for Chief Medical Officer
Sudha Parasuraman has been appointed chief medical officer of cancer drug developer Ribon Therapeutics. She was most recently the chief medical officer of X4 Pharmaceuticals (NASDAQ: [[ticker:XFOR]]). Her experience also include positions at uniQure (NASDAQ: [[ticker:QURE]]), Novartis (NYSE: [[ticker:NVS]]) and Millennium Pharmaceuticals. In other moves, Ribon named Edward “Tad” Stewart to serve as chief business … Continue reading “Ribon Therapeutics Taps Sudha Parasuraman for Chief Medical Officer”
Rhythm Pharma’s Obesity Drug Hits Phase 3 Goals, FDA Filing Planned
A Rhythm Pharmaceuticals drug developed to reduce the weight gain and ravenous hunger in genetic obesity disorders has hit the goals of two late-stage clinical trials, and the company now plans to file for FDA approvals late this year or in early 2020. On Wednesday, Rhythm (NASDAQ: [[ticker:RYTM]]) announced preliminary Phase 3 data for its … Continue reading “Rhythm Pharma’s Obesity Drug Hits Phase 3 Goals, FDA Filing Planned”
Editas Medicine Appoints Cynthia Collins President & CEO
Cynthia Collins has been appointed president and CEO of Editas Medicine (NASDAQ: [[ticker:EDIT]]). Collins has been serving as interim CEO of the Cambridge, MA, company since Katrine Bosley left the chief executive role in March. Collins will continue to serve on the Editas board of directors. Her experience includes executive roles at Human Longevity, the … Continue reading “Editas Medicine Appoints Cynthia Collins President & CEO”
Ex-Achaogen Exec Janet Dorling Joins CymaBay as Chief Commercial Officer
CymaBay Therapeutics (NASDAQ: [[ticker:CBAY]]) has appointed Janet Dorling to serve as its chief commercial officer, the same position she held at antibiotics developer Achaogen. Her experience also includes time at Roche subsidiary Genentech. Newark, CA-based CymaBay is developing drugs for liver diseases. In June, the company reported preliminary Phase 2 results showing that its lead … Continue reading “Ex-Achaogen Exec Janet Dorling Joins CymaBay as Chief Commercial Officer”
Genentech’s Hegde Named Foundation Medicine Chief Scientific Officer
Priti Hegde is now chief scientific officer of Foundation Medicine. She joins Cambridge, MA-based Foundation after 12 years at Roche subsidiary Genentech, where she was most recently senior director and principal scientist in oncology biomarker development. Hegde will take over the scientific responsibilities of Michael Doherty, who will retire in September from his position as … Continue reading “Genentech’s Hegde Named Foundation Medicine Chief Scientific Officer”
Allogene Taps Adaptimmune’s Rafael Amado as Chief Medical Officer
Rafael Amado has been appointed executive vice president of research and development and chief medical officer of Allogene Therapeutics (NASDAQ: [[ticker:ALLO]]). He joins the South San Francisco cancer drug developer from Adaptimmune, where he was president of research and development. His experience also includes positions at GlaxoSmithKline (NYSE: [[ticker:GSK]]) and Amgen (NASDAQ: [[ticker:AMGN]]). Amado is … Continue reading “Allogene Taps Adaptimmune’s Rafael Amado as Chief Medical Officer”
Inari Reaps $89M and Eyes Global Farm Markets for Gene-Edited Seeds
Plant genetics startup Inari, which is developing crop varieties that produce higher yields and use fewer resources, has raised $89 million to advance its research toward the US and international markets. Corn, soybean, wheat, and tomatoes are the Cambridge, MA-based company’s initial target crops. CEO Ponsi Trivisvavet says the company aims to launch several products … Continue reading “Inari Reaps $89M and Eyes Global Farm Markets for Gene-Edited Seeds”
Another Delay for Intra-Cellular as FDA Extends Review of Psych Drug
[Updated 1:33 p.m.] Intra-Cellular Therapies will have to wait another three months to see whether the FDA will approve its experimental drug for schizophrenia, which has produced mixed results in human studies but is currently under a regulatory review. The New York company said Monday that the FDA has pushed back the deadline for its … Continue reading “Another Delay for Intra-Cellular as FDA Extends Review of Psych Drug”
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
[Corrected 12:55 p.m. ET. See below.] Acquisitions made Pfizer what it is today: the world’s biggest drug maker measured by revenue. But as the company maps its future, CEO Albert Bourla is breaking some of that legacy apart. Blockbuster drugs such as Viagra, which was discovered in-house, and Lipitor, which came via acquisition, are currently … Continue reading “Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More”
Adverum Biotechnologies Executive Mehdi Gasmi to Retire
Gene therapy developer Adverum Biotechnologies (NASDAQ: [[ticker:ADVM]]) announced Thursday that Mehdi Gasmi, the company’s president and chief scientific officer, is retiring. When Gasmi retires on Sept. 16, he will join the Menlo Park, CA, company’s board of directors. He will also serve as a consultant to the business for six months. Adverum says a search … Continue reading “Adverum Biotechnologies Executive Mehdi Gasmi to Retire”
Frontier Medicines Adds Kevin Webster, Johannes Hermann to C-Suite
Frontier Medicines has appointed Kevin Webster to serve as the cancer drug developer’s chief scientific officer. Webster most recently worked at eFFECTOR Therapeutics as its senior vice president of cancer biology. Frontier also named Johannes Hermann its chief technology officer. Hermann was most recently senior director and global head for data sciences at Johnson & … Continue reading “Frontier Medicines Adds Kevin Webster, Johannes Hermann to C-Suite”
Elanco Boosts Vaccine Portfolio With $60M Prevtec Acquisition
One of the most serious threats to a young farm pig’s life is a type of gut infection that can quickly turn deadly. Elanco Animal Health has acquired a Canadian biotechnology startup that has commercialized a line of vaccines developed to protect pigs from the infection. Elanco (NYSE: [[ticker:ELAN]]) announced Thursday that it paid approximately … Continue reading “Elanco Boosts Vaccine Portfolio With $60M Prevtec Acquisition”
Pfizer’s Avagliano Joins G1 Therapeutics as Chief Business Officer
G1 Therapeutics (NASDAQ: [[ticker:GTHX]]) has tapped Mark Avagliano to become its chief business officer. Avagliano joins the Research Triangle Park, NC-based cancer drug developer from Pfizer (NYSE: [[ticker:PFE]]), where he was vice president of corporate development. Lead G1 drug candidate trilaciclib, which has been tested in small-cell lung cancer and metastatic triple-negative breast cancer, is … Continue reading “Pfizer’s Avagliano Joins G1 Therapeutics as Chief Business Officer”
White House Floats Canadian Import Plan But Excludes Many Costly Drugs
[Updated, 6:18 p.m. ET. See below.] The Trump administration unveiled Wednesday a long-awaited plan to import cheaper medications from Canada and other countries. The US Department of Health and Human Services says the two proposals are part of the administration’s strategy to curb high prescription-drug prices, which has often been short on action despite the … Continue reading “White House Floats Canadian Import Plan But Excludes Many Costly Drugs”
Verastem Oncology Board Member Brian Stuglik Named CEO
Brian Stuglik has been appointed CEO of Verastem Oncology (NASDAQ: [[ticker:VSTM]]). Stuglik is a member of the Boston-based cancer drug developer’s board of directors, and he will retain his board seat. His experience also includes various positions at Eli Lilly (NYSE: [[ticker:LLY]]). Stuglik succeeds Robert Forrester, who stepped down in June.
Sherlock Bio Names Harvard’s William Blake Chief Technology Officer
Sherlock Biosciences has appointed William Blake to serve as its chief technology officer. Blake most recently worked at Harvard, where he was the business development lead for the Wyss Institute for Biologically Inspired Engineering. His experience also includes posts at GreenLight Biosciences and Codon Devices. In other moves, Cambridge, MA-based Sherlock named Don Haut its … Continue reading “Sherlock Bio Names Harvard’s William Blake Chief Technology Officer”